ArticleAnnals of intensive care2025
Neurally adjusted ventilatory assist in critical care patients with and without obesity: a prospective randomized crossover study.
Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurally Adjusted Ventilatory Assist (NAVA) compared to Pressure Support Ventilation (PSV) improves patient-ventilator interactions in intensive care unit. No study has evaluated NAVA in patients with obesity. We aimed to assess the feasibility and safety of NAVA in patients with obesity, and to compare NAVA in patients with versus without obesity.
methodsIn this randomized cross-over study, all respiratory cycles during 1 h of mechanical ventilation from 10 patients with obesity and 11 without obesity were analyzed. Patients underwent 30 min of NAVA and 30 min of PSV in a random order. Flow, airway pressure and diaphragm electrical activity were continuously recorded. Arterial blood gases were obtained at baseline and at the end of each 30-min period. Patient-ventilator interactions were assessed with trigger delay, inspiratory time in excess, rate and type of dyssynchrony cycles. Variability of the ventilatory parameters was evaluated by the coefficient of variation (SD/mean).
resultsAll patients concluded the study, with a total of 1790 ± 873 respiratory cycles analyzed per patient. In patients with obesity, NAVA versus PSV was associated with a significant reduction in trigger delay (0 [0-5] vs. 106 [34-125] ms, p < 0.05), inspiratory time in excess (96 [94-102] vs. 145 [137-202] ms, p < 0.01) and in ineffective efforts (0 [0-0.03] vs. 0.33 [0.23-0.37] events/min, p < 0.05). The global dyssynchrony index remained similar in both modes (2.2% [1.1-4.4] vs. 3.7% [2.4-5.6], p = 0.68). Compared to PSV, PaO2/FiO2 ratio significantly increased in NAVA, 238 mmHg [174-344] versus 207 mmHg [164-297], p < 0.05. The tidal volume was significantly lower during NAVA than during PSV, 6.7 mL/kg predicted body weight [5.9-7.1] versus 7.2 mL/kg [6.2-8.2], p < 0.05. Ventilatory variability was significantly higher with NAVA, 16% [11-21] versus 4% [2-4] in mean inspiratory airway pressure. These results were similar in patients without obesity and the obesity factor was never significant. No adverse event was observed in patients with and without obesity in both modes.
conclusionIn patients with obesity, NAVA ventilation is feasible and safe, improves patient-ventilator interactions and oxygenation, with an increase ventilatory variability compared to PSV. The effects of NAVA are comparable in patients with and without obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.